Long-term survivors after chemotherapy in advanced non-small cell lung cancer

Anticancer Research

Volumn 27, Issue 6 C, 2007, Pages 4457-4460

  Satoh, Hiroaki ^a   Ishikawa, Hiroichi ^a   Ohara, Gen ^a   Kagohashi, Katsunori ^a   Kurishima, Koichi ^a   Ohtsuka, Morio ^a   Hizawa, Nobuyuki ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Chemotherapy; Gefitinib; Long term survival; Non small cell lung cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEFITINIB; GEMCITABINE; IRINOTECAN; NAVELBINE; PACLITAXEL; VINDESINE;

ARTICLE; CANCER CHEMOTHERAPY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SURVIVAL TIME; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; ETOPOSIDE; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; PROGNOSIS; QUINAZOLINES; SURVIVORS; TAXOIDS; TIME; VINBLASTINE; VINDESINE;

EID: 37549045957     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Novell S and Le Chevalier T: Chemotherapy for non-small cell lung cancer. Part 1. Early-stage disease. Oncology (Williston Park) 17: 357-364, 2003.
2. Belani CP and Langer C; TAX 326 Study Group: First-line chemotherapy for NSCLC: an overview of relevant trials. Lung Cancer 38(Suppl 4): 13-19, 2002.
3. Socinski MA: Cytotoxic chemotherapy in advanced non-small cell lung cancer: a review of standard treatment paradigms. Clin Cancer Res 10(12 Pt 2): 4210s-4214s, 2004.
4. Molina JR, Adjei AA and Jett JR: Advances in chemotherapy of non-small cell lung cancer. Chest 130: 1211-1219, 2006.
5. Nicum S and Cullen MH: Chemotherapy versus palliative care in non-small cell lung cancer. Anticancer Drugs 11: 603-607, 2000.
6. Cortes-Funes H: New treatment approaches for lung cancer and impact on survival. Semin Oncol 29(3 Suppl 8): 26-29, 2002.
7. Stinchcombe TE, Lee CB and Socinski MA: Current approaches to advanced-stage non-small-cell lung cancer: first-line therapy in patients with a good functional status. Clin Lung Cancer 7(Suppl 4): S111-S117, 2006.
8. Mountain CF: Revisions in the international system for staging lung cancer. Chest 111: 1710-1717, 1997.
9. World Health Organization. Histological Typing of Lung and Pleural Tumours. In: International Histological Classification of Tumours. 3rd edition, Geneva, 1999.
10. Kaplan EI and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
11. Cox DR: Regression models and life tables. JR Statist Soc B 34: 187-220, 1972.
12. Fikkelstein DM, Ettinger DS and Ruckdeschel JL: Long-term survivors in metastatic non-small cell lung cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol 4: 702-709, 1986.
13. Albain KS, Crowley JJ, LeBlanc M and Livingston RB: Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 9: 1618-1626, 1991.
14. Sculier JP, Paesmans M, Libert P et al: Long-term survival after chemotherapy containing platinum derivatives in patients with advanced unresectable non-small cell lung cancer. European Lung Cancer Working Party. Eur J Cancer 30A: 1342-1347, 1994.
15. Wagner W, Striehn E, Klinke F, Bosse U and Rube C: Analysis of long-term survival in patients with locally advanced non-small cell lung cancer. Oncol Rep 5: 1547-1550, 1998.
16. Satoh H, Ishikawa H, Yamashita YT et al: Analysis of long-term survivors after platinum containing chemotherapy in advanced non-small cell lung cancer. Anticancer Res 18: 1295-1298, 1998.